Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Azenta (AZTA)

Azenta Acquires UK Biocentre for GBP 20.5 Million to Expand European Sample Storage

Mixed Impact 3 of 5 m&a Written later

On March 4, 2026, Azenta's UK subsidiary acquired UK Biocentre Limited, a UK provider of sample management and storage services, for GBP 20.5 million net of cash, including up to GBP 1.8 million in milestone-based contingent consideration. Azenta expects the deal to reduce its 2026 Adjusted EBITDA margin on a pro forma basis, while adding to its 2027 and 2028 organic revenue growth and margin expansion expectations.

Key points

  • Total consideration of GBP 20.5 million, net of cash, including up to GBP 1.8 million contingent on milestones
  • UK Biocentre generated about GBP 15.3 million in revenue for the twelve months ended September 30, 2025
  • Expected to be dilutive to 2026 Adjusted EBITDA margin by about 35 basis points on a pro forma fiscal-year basis
  • Expected to be accretive to 2027 and 2028 organic revenue growth and Adjusted EBITDA margin expansion expectations

The filing

CompanyAzenta (AZTA)
Form8-K, current report
Filed with the SECMar 4, 2026, 9:15 AM ET
Accession number0001437749-26-006821

Items reported: 1.01 Material Definitive Agreement7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:55 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on March 04, 2026.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.